Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 7/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901529 | 0.89 | ALDH1A1 (0.56) | ALDH1A1RECQLNR1I2GAACYP3A4 | |
| SCHEMBL12517382 | 0.89 | LTA4H (0.56) | LTA4HPLA2G2APPARA | |
| SCHEMBL347186 | 0.89 | ALDH1A1 (0.65) | ALDH1A1RECQLLTA4HNR1I2GAA | |
| SCHEMBL12517331 | 0.89 | APP (0.53) | ALDH1A1RECQLLTA4HNR1I2CYP3A4 | |
| SCHEMBL27982425 | 0.87 | ALDH1A1 (0.62) | ALDH1A1RECQLLTA4HNR1I2GAA | |
| Ethylene Glycol SCHEMBL27348084 | 0.87 | ALDH1A1 (0.62) | ALDH1A1RECQLLTA4HNR1I2GAA | |
| SCHEMBL12517398 | 0.83 | LTA4H (0.71) | LTA4H | |
| SCHEMBL11538545 | 0.83 | LTA4H (0.54) | ALDH1A1RECQLLTA4HNR1I2GAA | |
| SCHEMBL14901530 | 0.82 | ALDH1A1 (0.48) | ALDH1A1RECQLNR1I2GAACYP3A4 | |
| SCHEMBL28106819 | 0.82 | ALDH1A1 (0.75) | ALDH1A1RECQLNR1I2GAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | SHBG, KLK3, HSD17B11 | ALDH1A1 179/4885RECQL 1492/4885LTA4H 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.